The compound you described, **1-(5-methyl-2-furanyl)-2-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-1H-[1]benzopyrano[2,3-c]pyrrole-3,9-dione**, is a complex organic molecule with a unique structure. It is important for research due to its potential biological activities. However, I cannot provide specific information on its importance without more context.
Here's why:
* **Its chemical structure is highly specific:** The compound has a long and complex chemical name indicating its specific arrangement of atoms. This precise structure is crucial for its biological activity.
* **Biological activity is context-dependent:** The importance of this compound would depend on its intended use. Is it being studied as a potential drug candidate? Is it being used as a tool to probe a specific biological pathway? The answer will determine what makes it important for research.
To provide more specific information about its importance, I need additional details about the research context. For example,
* **What type of research is being conducted?** (e.g., drug discovery, medicinal chemistry, biological studies)
* **What specific biological activity is being investigated?** (e.g., anti-cancer, antibacterial, antiviral)
* **What is the research question being addressed?**
Once you provide more context, I can help you understand why this specific compound is important for the research in question.
| ID Source | ID |
|---|---|
| PubMed CID | 4228694 |
| CHEMBL ID | 1413422 |
| CHEBI ID | 105220 |
| Synonym |
|---|
| smr000092298 |
| MLS000115050 , |
| CHEBI:105220 |
| STK819367 |
| 1-(5-methylfuran-2-yl)-2-[5-(propan-2-yl)-1,3,4-thiadiazol-2-yl]-1,2-dihydrochromeno[2,3-c]pyrrole-3,9-dione |
| AKOS001691951 |
| NCGC00082630-02 |
| 1-(5-methylfuran-2-yl)-2-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-1h-chromeno[2,3-c]pyrrole-3,9-dione |
| HMS2265J11 |
| CCG-25082 |
| AB00429658-10 |
| AKOS016087680 |
| 1-(5-methylfuran-2-yl)-2-[5-(propan-2-yl)-1,3,4-thiadiazol-2-yl]-1h,2h,3h,9h-chromeno[2,3-c]pyrrole-3,9-dione |
| CHEMBL1413422 |
| Q27182927 |
| 1-(5-methyl-2-furanyl)-2-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-1h-[1]benzopyrano[2,3-c]pyrrole-3,9-dione |
| Class | Description |
|---|---|
| chromones | A chromenone that consists of a 1,4-benzopyrone skeleton and its substituted derivatives thereof. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 5.0119 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 25.1189 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| TDP1 protein | Homo sapiens (human) | Potency | 14.6777 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 8.9125 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| 67.9K protein | Vaccinia virus | Potency | 10.6101 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 19.9526 | 0.3162 | 12.4435 | 31.6228 | AID924 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 28.1838 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 31.6228 | 6.3096 | 60.2008 | 112.2020 | AID720709 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 19.9526 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 19.9526 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||